Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Upgraded by UBS Group

UBS Group upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ - Free Report) from a neutral rating to a buy rating in a research report report published on Friday, MarketBeat reports. UBS Group currently has $179.00 target price on the specialty pharmaceutical company's stock, up from their previous target price of $145.00.

Several other analysts have also recently weighed in on JAZZ. Barclays reaffirmed an "overweight" rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. TD Cowen cut their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. JPMorgan Chase & Co. raised their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, Royal Bank of Canada cut their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $189.40.

Remove Ads

Jazz Pharmaceuticals Stock Up 1.7 %

NASDAQ:JAZZ traded up $2.36 during mid-day trading on Friday, hitting $138.81. The stock had a trading volume of 1,226,548 shares, compared to its average volume of 763,953. The stock has a 50-day simple moving average of $128.14 and a two-hundred day simple moving average of $120.03. The company has a market capitalization of $8.43 billion, a PE ratio of 19.55, a PEG ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the transaction, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,193 shares of company stock valued at $3,533,122 in the last ninety days. 4.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. CWA Asset Management Group LLC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after purchasing an additional 100,112 shares in the last quarter. Centre Asset Management LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth $9,335,000. Moloney Securities Asset Management LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth $464,000. Finally, Pacer Advisors Inc. boosted its position in shares of Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock worth $233,892,000 after purchasing an additional 278,465 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.